Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) Q code for Biovance 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap that acts as a scaffold for restoration of functional tissue in partial- and full-thickness, acute and chronic wounds. The designated HCPCS Q code is Q4283 and is available starting April 1, 2024.
開發胎盤衍生異基因細胞療法和先進生物材料產品的再生醫學公司Celularity Inc.（納斯達克股票代碼：CELU）（“Celularity”）今天宣佈，美國醫療保險和醫療補助服務中心（CMS）已授予Biovance 3L的醫療保健通用程序編碼系統（HCPCS）Q碼，這是一種源自胎盤組織的三層同種異體移植物用作覆蓋屏障的生物膜或包裹，用作修復局部和全厚度、急性和慢性傷口功能組織的支架。指定的 HCPCS Q 代碼爲 Q4283，自 2024 年 4 月 1 日起上線。
"The HCPCS Q code approval by CMS further recognizes Biovance 3L as an important therapeutic option for the treatment of wounds," said Dr. Robert J. Hariri, M.D., Ph.D., Celularity CEO, chairman and founder. "The medical community has been rapidly adopting this product, and the HCPCS Q code approval paves the way for Biovance 3L to realize additional growth, enabling the potential to impact more lives. As one of our leading biomaterial products, we are excited about the potential impact this approval may have on Celularity's performance throughout the remainder of 2024 and beyond. We will continue to innovate in this important part of our business and look forward to providing future updates."
Celularity首席執行官、董事長兼創始人羅伯特·哈里里博士說：“CMS批准的HCPCSQ代碼進一步認可Biovance 3L是治療傷口的重要治療選擇。”“醫學界一直在迅速採用該產品，HCPCS Q碼批准爲Biovance 3L實現額外增長鋪平了道路，從而有可能影響更多生活。作爲我們領先的生物材料產品之一，我們對該批准可能對Celularity在2024年剩餘時間及以後的業績產生的潛在影響感到興奮。我們將繼續在業務的這一重要部分進行創新，並期待提供未來的更新。”
The Healthcare Common Procedure Coding System (HCPCS) is produced by the Centers for Medicare and Medicaid Services (CMS). HCPCS is a group of standardized codes that represent medical procedures, supplies, products, and services. The codes are used to facilitate the processing of health insurance claims by Medicare and other insurers. The Q codes are established to identify drugs, biologicals, and medical equipment or services not identified by national HCPCS Level II codes but for which codes are needed for Medicare claims processing. HCPCS code modifiers are established internally by CMS to facilitate accurate Medicare claims processing.
醫療保健通用程序編碼系統（HCPCS）由醫療保險和醫療補助服務中心（CMS）制定。HCPCS 是一組代表醫療程序、用品、產品和服務的標準化代碼。這些守則用於促進醫療保險和其他保險公司處理健康保險索賠。Q代碼的建立是爲了識別藥物、生物製劑和醫療設備或服務，這些藥物、生物製品和醫療設備或服務未被國家HCPCS二級代碼識別，但醫療保險索賠處理需要哪些代碼。HCPCS 代碼修改器由 CMS 內部建立，旨在促進準確的醫療保險索賠處理。
Biovance 3L's unique tri-layer membrane construction is designed for improved handling and ease of use as a covering, barrier, or wrap to surgical sites. The three-dimensional design provides more surface area, allows for suturing as required, and serves as a cell-friendly structure that promotes cell attachment within hours.
Biovance 3L 獨特的三層膜結構旨在改善操作性並易於使用，可用作手術部位的覆蓋物、屏障或包裹。三維設計可提供更大的表面積，允許根據需要進行縫合，並且是一種細胞友好結構，可在數小時內促進細胞附着。
譯文內容由第三人軟體翻譯。